Screener
BridgeBio Pharma BBIO Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| 2028 | 4,744 | 10,063 | 16,819 | — | 31,626 | |||||
| 2029 | 4,744 | 10,063 | 755,909 | — | 770,716 | |||||
| 2030 | 4,744 | 10,063 | — | — | 14,807 | |||||
| 2031 | 4,744 | 580,031 | — | — | 584,775 | |||||
| Thereafter | 639,616 | — | — | — | 639,616 | |||||
| Total future payments | 665,853 | 625,314 | 797,956 | 563,750 | 2,652,873 | |||||
| Less amounts representing interest | (33,353) | (50,314) | (50,456) | (13,750) | (147,873) | |||||
| Total principal amount | $ | $632,500 | $ | $575,000 | $ | $747,500 | $ | $550,000 | $ | $2,505,000 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's long-term debt?
- BridgeBio Pharma (BBIO) reported long-term debt of $2.65B in Q1 2026.
- What is the long-term trend for BridgeBio Pharma's long-term debt?
- Over 4 years (2020 to 2024), BridgeBio Pharma's long-term debt has grown at a 47.5% compound annual growth rate (CAGR), from $92.42M to $437.34M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about BridgeBio Pharma's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude